{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:09Z","timestamp":1792783329428,"version":"4.5.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bollenstreekfonds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11523-026-01220-5","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:23:20Z","timestamp":1777289000000},"page":"357-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Strategies Targeting the Tumor\u2013Stromal Microenvironment in Colorectal Cancer: A Narrative Review"],"prefix":"10.1007","volume":"21","author":[{"given":"Floor","family":"Heilijgers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"van Hest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Speetjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen C. M. J.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Roodhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5533-4778","authenticated-orcid":false,"given":"Wilma E.","family":"Mesker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"1","key":"1220_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"1220_CR2","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"key":"1220_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1161048","volume":"13","author":"A Gandini","year":"2023","unstructured":"Gandini A, Puglisi S, Pirrone C, Martelli V, Catalano F, Nardin S, et al. The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives. Front Oncol. 2023;13:1161048. https:\/\/doi.org\/10.3389\/fonc.2023.1161048.","journal-title":"Front Oncol"},{"issue":"1","key":"1220_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/gut.2008.155473","volume":"58","author":"S Ogino","year":"2009","unstructured":"Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90\u20136. https:\/\/doi.org\/10.1136\/gut.2008.155473.","journal-title":"Gut"},{"issue":"1","key":"1220_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.34172\/bi.2021.02","volume":"11","author":"R Dolatkhah","year":"2021","unstructured":"Dolatkhah R, Dastgiri S, Eftekhar Sadat AT, Farassati F, Nezamdoust M, Somi MH. Impact of RAS\/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer. Bioimpacts. 2021;11(1):5\u201314. https:\/\/doi.org\/10.34172\/bi.2021.02.","journal-title":"Bioimpacts"},{"issue":"2","key":"1220_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000489","volume":"4","author":"C Cremolini","year":"2019","unstructured":"Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fuc\u00e0 G, et al. Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open. 2019;4(2):e000489. https:\/\/doi.org\/10.1136\/esmoopen-2019-000489.","journal-title":"ESMO Open."},{"issue":"9","key":"1220_CR7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/modpathol.2017.46","volume":"30","author":"A Lugli","year":"2017","unstructured":"Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299\u2013311. https:\/\/doi.org\/10.1038\/modpathol.2017.46.","journal-title":"Mod Pathol"},{"issue":"21","key":"1220_CR8","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/jnci\/djs427","volume":"104","author":"AD Roth","year":"2012","unstructured":"Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II\/III colon cancer. J Natl Cancer Inst. 2012;104(21):1635\u201346. https:\/\/doi.org\/10.1093\/jnci\/djs427.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1220_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10620-024-08774-2","volume":"70","author":"N Fatemi","year":"2025","unstructured":"Fatemi N, Mirbahari SN, Tierling S, Sanjabi F, Shahrivari S, AmeliMojarad M, et al. Emerging frontiers in colorectal cancer therapy: from targeted molecules to immunomodulatory breakthroughs and cell-based approaches. Dig Dis Sci. 2025;70(3):919\u201342. https:\/\/doi.org\/10.1007\/s10620-024-08774-2.","journal-title":"Dig Dis Sci"},{"issue":"16","key":"1220_CR10","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081.","journal-title":"Curr Biol"},{"issue":"1","key":"1220_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159. https:\/\/doi.org\/10.1186\/s12943-023-01860-5.","journal-title":"Mol Cancer"},{"issue":"4","key":"1220_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/jcb.21159","volume":"101","author":"H Li","year":"2007","unstructured":"Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007;101(4):805\u201315. https:\/\/doi.org\/10.1002\/jcb.21159.","journal-title":"J Cell Biochem"},{"issue":"5","key":"1220_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1155\/2007\/175276","volume":"29","author":"WE Mesker","year":"2007","unstructured":"Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol. 2007;29(5):387\u201398. https:\/\/doi.org\/10.1155\/2007\/175276.","journal-title":"Cell Oncol"},{"issue":"3","key":"1220_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/clo-2009-0478","volume":"31","author":"WE Mesker","year":"2009","unstructured":"Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, et al. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol. 2009;31(3):169\u201378. https:\/\/doi.org\/10.3233\/clo-2009-0478.","journal-title":"Cell Oncol"},{"issue":"4","key":"1220_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102988","volume":"9","author":"M Polack","year":"2024","unstructured":"Polack M, Smit MA, van Pelt GW, Roodvoets AGH, Meershoek-Klein Kranenbarg E, Putter H, et al. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor\u2013stroma ratio in colon cancer. ESMO Open. 2024;9(4):102988. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102988.","journal-title":"ESMO Open"},{"key":"1220_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100247","volume":"25","author":"MA Smit","year":"2020","unstructured":"Smit MA, Philipsen MW, Postmus PE, Putter H, Tollenaar RA, Cohen D, et al. The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study. Cancer Treat Res Commun. 2020;25:100247. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100247.","journal-title":"Cancer Treat Res Commun"},{"issue":"8","key":"1220_CR17","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/ijc.32857","volume":"146","author":"KMH Vangangelt","year":"2020","unstructured":"Vangangelt KMH, Green AR, Heemskerk IMF, Cohen D, van Pelt GW, Sobral-Leite M, et al. The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. Int J Cancer. 2020;146(8):2296\u2013304. https:\/\/doi.org\/10.1002\/ijc.32857.","journal-title":"Int J Cancer"},{"key":"1220_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctro.2019.11.003","volume":"20","author":"GW van Pelt","year":"2020","unstructured":"van Pelt GW, Krol JA, Lips IM, Peters FP, van Klaveren D, Boonstra JJ, et al. The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer. Clin Transl Radiat Oncol. 2020;20:39\u201344. https:\/\/doi.org\/10.1016\/j.ctro.2019.11.003.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1220_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.685570","volume":"11","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Jin Z, Qian Y, Shen Y, Wang Z. Prognostic value of tumor-stroma ratio in rectal cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:685570. https:\/\/doi.org\/10.3389\/fonc.2021.685570.","journal-title":"Front Oncol"},{"issue":"16_suppl","key":"1220_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3134","volume":"43","author":"I Franken","year":"2025","unstructured":"Franken I, Heilijgers F, Bakker M-C, Rubio-Alarcon C, Crnovrsanin N, Lemmens M, et al. Combined prognostic value of post-surgery circulating tumor DNA and tumor-stroma ratio in patients with stage III colon cancer treated with adjuvant chemotherapy. J Clin Oncol. 2025;43(16_suppl):3134. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3134.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1220_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/his.15423","volume":"87","author":"M Polack","year":"2025","unstructured":"Polack M, van Pelt GW, van den Heuvel DH, Klein-Kranenbarg EM, Roodvoets AGH, Putter H, et al. The tumour-stroma ratio as predictive aid towards a biopsy-based treatment strategy in rectal carcinoma. Histopathology. 2025;87(1):44\u201357. https:\/\/doi.org\/10.1111\/his.15423.","journal-title":"Histopathology"},{"issue":"4","key":"1220_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jnci\/djab106","volume":"114","author":"S Ten Hoorn","year":"2022","unstructured":"Ten Hoorn S, de Back TR, Sommeijer DW, Vermeulen L. Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2022;114(4):503\u201316. https:\/\/doi.org\/10.1093\/jnci\/djab106.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1220_CR23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reyni\u00e8s A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350\u20136. https:\/\/doi.org\/10.1038\/nm.3967.","journal-title":"Nat Med"},{"issue":"4","key":"1220_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320\u20139. https:\/\/doi.org\/10.1038\/ng.3225.","journal-title":"Nat Genet"},{"key":"1220_CR25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25845","author":"TP Sandberg","year":"2018","unstructured":"Sandberg TP, Oosting J, van Pelt GW, Mesker WE, Tollenaar RAEM, Morreau H. Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio\u2014increased expression of galectin-1 in tumors with high stromal content. Oncotarget. 2018. https:\/\/doi.org\/10.18632\/oncotarget.25845.","journal-title":"Oncotarget"},{"issue":"2","key":"1220_CR26","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/cancers3022160","volume":"3","author":"J Conti","year":"2011","unstructured":"Conti J, Thomas G. The role of tumour stroma in colorectal cancer invasion and metastasis. Cancers (Basel). 2011;3(2):2160\u20138. https:\/\/doi.org\/10.3390\/cancers3022160.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1220_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/cam4.4452","volume":"11","author":"KM Brown","year":"2022","unstructured":"Brown KM, Xue A, Smith RC, Samra JS, Gill AJ, Hugh TJ. Cancer-associated stroma reveals prognostic biomarkers and novel insights into the tumour microenvironment of colorectal cancer and colorectal liver metastases. Cancer Med. 2022;11(2):492\u2013506. https:\/\/doi.org\/10.1002\/cam4.4452.","journal-title":"Cancer Med"},{"key":"1220_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051130","author":"C Galindo-Pumari\u00f1o","year":"2021","unstructured":"Galindo-Pumari\u00f1o C, Collado M, Herrera M, Pe\u00f1a C. Tumor microenvironment in metastatic colorectal cancer: the arbitrator in patients\u2019 outcome. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13051130.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1220_CR29","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1002\/bjs.10788","volume":"105","author":"I Ubink","year":"2018","unstructured":"Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg. 2018;105(2):e204\u201311. https:\/\/doi.org\/10.1002\/bjs.10788.","journal-title":"Br J Surg"},{"issue":"6","key":"1220_CR30","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s12094-021-02746-y","volume":"24","author":"MTA Strous","year":"2022","unstructured":"Strous MTA, Faes TKE, Gubbels ALHM, van der Linden RLA, Mesker WE, Bosscha K, et al. A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance. Clin Transl Oncol. 2022;24(6):1047\u201358. https:\/\/doi.org\/10.1007\/s12094-021-02746-y.","journal-title":"Clin Transl Oncol"},{"key":"1220_CR31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4172\/2472-4971.1000116","volume":"1","author":"G Van Pelt","year":"2016","unstructured":"Van Pelt G, Hansen T, Bastiaannet E, Frifeldt S, Van Krieken J, Tollenaar R, et al. Stroma-high lymph node involvement predicts poor survival more accurately for patients with stage III colon cancer. J Med Surg Pathol. 2016;1:116.","journal-title":"J Med Surg Pathol."},{"issue":"5","key":"1220_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2559.1985.tb02830.x","volume":"9","author":"S Fossum","year":"1985","unstructured":"Fossum S, Ford WL. The organization of cell populations within lymph nodes: their origin, life history and functional relationships. Histopathology. 1985;9(5):469\u201399. https:\/\/doi.org\/10.1111\/j.1365-2559.1985.tb02830.x.","journal-title":"Histopathology"},{"issue":"14","key":"1220_CR33","first-page":"3327","volume":"53","author":"WJ Rettig","year":"1993","unstructured":"Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993;53(14):3327\u201335.","journal-title":"Cancer Res"},{"issue":"6","key":"1220_CR34","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1200\/jco.1994.12.6.1193","volume":"12","author":"S Welt","year":"1994","unstructured":"Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12(6):1193\u2013203. https:\/\/doi.org\/10.1200\/jco.1994.12.6.1193.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1220_CR35","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"MJ Scanlan","year":"1994","unstructured":"Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994;91(12):5657\u201361. https:\/\/doi.org\/10.1073\/pnas.91.12.5657.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1220_CR36","first-page":"1639","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9(5):1639\u201347.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1220_CR37","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55(7):1322\u201332. https:\/\/doi.org\/10.1038\/s12276-023-01013-0.","journal-title":"Exp Mol Med"},{"issue":"5","key":"1220_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"10","key":"1220_CR39","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.7150\/thno.55074","volume":"11","author":"X Wan","year":"2021","unstructured":"Wan X, Guan S, Hou Y, Qin Y, Zeng H, Yang L, et al. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts. Theranostics. 2021;11(10):4975\u201391. https:\/\/doi.org\/10.7150\/thno.55074.","journal-title":"Theranostics."},{"issue":"6","key":"1220_CR40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719\u201334. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.005.","journal-title":"Cancer Cell"},{"issue":"6","key":"1220_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735\u201347. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.021.","journal-title":"Cancer Cell"},{"issue":"1","key":"1220_CR42","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41467-023-36334-1","volume":"14","author":"J Linares","year":"2023","unstructured":"Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, M\u00e9ndez A, Manero-Rup\u00e9rez N, et al. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Nat Commun. 2023;14(1):746. https:\/\/doi.org\/10.1038\/s41467-023-36334-1.","journal-title":"Nat Commun"},{"issue":"7693","key":"1220_CR43","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538\u201343. https:\/\/doi.org\/10.1038\/nature25492.","journal-title":"Nature"},{"issue":"9","key":"1220_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","volume":"9","author":"MB Meads","year":"2009","unstructured":"Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9(9):665\u201374. https:\/\/doi.org\/10.1038\/nrc2714.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1220_CR45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","volume":"172","author":"S Su","year":"2018","unstructured":"Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841-56.e16. https:\/\/doi.org\/10.1016\/j.cell.2018.01.009.","journal-title":"Cell"},{"issue":"1","key":"1220_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"B Feng","year":"2022","unstructured":"Feng B, Wu J, Shen B, Jiang F, Feng J. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. Cancer Cell Int. 2022;22(1):166. https:\/\/doi.org\/10.1186\/s12935-022-02599-7.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"1220_CR47","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2174\/156652412803833607","volume":"12","author":"M Jacob","year":"2012","unstructured":"Jacob M, Chang L, Pur\u00e9 E. Fibroblast activation protein in remodeling tissues. Curr Mol Med. 2012;12(10):1220\u201343. https:\/\/doi.org\/10.2174\/156652412803833607.","journal-title":"Curr Mol Med"},{"issue":"6","key":"1220_CR48","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/1078-0432.Ccr-06-1746","volume":"13","author":"LR Henry","year":"2007","unstructured":"Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736\u201341. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-1746.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1220_CR49","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ajpath.2010.12.008","volume":"178","author":"ML Henriksson","year":"2011","unstructured":"Henriksson ML, Edin S, Dahlin AM, Oldenborg PA, \u00d6berg \u00c5, Van Guelpen B, et al. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1\/FGFR3 signaling and increased invasion. Am J Pathol. 2011;178(3):1387\u201394. https:\/\/doi.org\/10.1016\/j.ajpath.2010.12.008.","journal-title":"Am J Pathol"},{"key":"1220_CR50","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3389\/fonc.2020.00979","volume":"10","author":"M Coto-Llerena","year":"2020","unstructured":"Coto-Llerena M, Ercan C, Kancherla V, Taha-Mehlitz S, Eppenberger-Castori S, Soysal SD, et al. High expression of FAP in colorectal cancer is associated with angiogenesis and immunoregulation processes. Front Oncol. 2020;10:979. https:\/\/doi.org\/10.3389\/fonc.2020.00979.","journal-title":"Front Oncol"},{"issue":"3","key":"1220_CR51","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3892\/ijo.2011.906","volume":"38","author":"S Saigusa","year":"2011","unstructured":"Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Okugawa Y, Fujikawa H, et al. Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J Oncol. 2011;38(3):655\u201363. https:\/\/doi.org\/10.3892\/ijo.2011.906.","journal-title":"Int J Oncol"},{"issue":"5","key":"1220_CR52","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/cancers13051100","volume":"13","author":"S Koustoulidou","year":"2021","unstructured":"Koustoulidou S, Hoorens MWH, Dalm SU, Mahajan S, Debets R, Seimbille Y, et al. Cancer-associated fibroblasts as players in cancer development and progression and their role in targeted radionuclide imaging and therapy. Cancers (Basel). 2021;13(5):1100. https:\/\/doi.org\/10.3390\/cancers13051100.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"1220_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cpet.2021.03.012","volume":"16","author":"K Dendl","year":"2021","unstructured":"Dendl K, Schlittenhardt J, Staudinger F, Kratochwil C, Altmann A, Haberkorn U, et al. The role of fibroblast activation protein ligands in oncologic PET imaging. PET Clinics. 2021;16(3):341\u201351. https:\/\/doi.org\/10.1016\/j.cpet.2021.03.012.","journal-title":"PET Clinics"},{"issue":"3","key":"1220_CR54","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386. https:\/\/doi.org\/10.2967\/jnumed.118.215913.","journal-title":"J Nucl Med"},{"issue":"9","key":"1220_CR55","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","volume":"61","author":"SA Koerber","year":"2020","unstructured":"Koerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, et al. The role of Ga-FAPI PET\/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience. J Nuclear Med. 2020;61(9):1331\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.237016.","journal-title":"J Nuclear Med."},{"issue":"1","key":"1220_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41416-022-01748-z","volume":"127","author":"E Strating","year":"2022","unstructured":"Strating E, Wassenaar E, Verhagen M, Rauwerdink P, van Schelven S, de Hingh I, et al. Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging. Br J Cancer. 2022;127(1):145\u201355. https:\/\/doi.org\/10.1038\/s41416-022-01748-z.","journal-title":"Br J Cancer"},{"key":"1220_CR57","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5098728","author":"M Polack","year":"2025","unstructured":"Polack M, van Pelt GW, Crobach ASLP, de Geus-Oei L, Tollenaar RAEM, van Krieken HJM, et al. Fibroblast activation protein-expression in colorectal carcinomas and implications for clinical application. Soc Sci Res Netw. 2025. https:\/\/doi.org\/10.2139\/ssrn.5098728.","journal-title":"Soc Sci Res Netw"},{"issue":"16","key":"1220_CR58","first-page":"4767","volume":"62","author":"JD Cheng","year":"2002","unstructured":"Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002;62(16):4767\u201372.","journal-title":"Cancer Res"},{"issue":"3","key":"1220_CR59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/1535-7163.Mct-04-0269","volume":"4","author":"JD Cheng","year":"2005","unstructured":"Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther. 2005;4(3):351\u201360. https:\/\/doi.org\/10.1158\/1535-7163.Mct-04-0269.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1220_CR60","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000069863","volume":"26","author":"RD Hofheinz","year":"2003","unstructured":"Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, J\u00e4ger D, Renner C, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003;26(1):44\u20138. https:\/\/doi.org\/10.1159\/000069863.","journal-title":"Onkologie"},{"issue":"11","key":"1220_CR61","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.4161\/cbt.6.11.4874","volume":"6","author":"K Narra","year":"2007","unstructured":"Narra K, Ms R, L H-O, S-B B, M K, Cv J, et al. Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007;6(11):1691\u20139. https:\/\/doi.org\/10.4161\/cbt.6.11.4874.","journal-title":"Cancer Biol Ther"},{"issue":"23","key":"1220_CR62","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.1158\/0008-5472.Can-10-4660","volume":"71","author":"L Lin","year":"2011","unstructured":"Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011;71(23):7226\u201337. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-4660.","journal-title":"Cancer Res"},{"issue":"6","key":"1220_CR63","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/1078-0432.Ccr-10-2694","volume":"17","author":"T Morikawa","year":"2011","unstructured":"Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 2011;17(6):1452\u201362. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2694.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1220_CR64","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1073\/pnas.1424171112","volume":"112","author":"Y Li","year":"2015","unstructured":"Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015;112(6):1839\u201344. https:\/\/doi.org\/10.1073\/pnas.1424171112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1220_CR65","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/s2468-1253(18)30009-8","volume":"3","author":"DJ Jonker","year":"2018","unstructured":"Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(4):263\u201370. https:\/\/doi.org\/10.1016\/s2468-1253(18)30009-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1220_CR66","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1593\/neo.06820","volume":"9","author":"SA Tsareva","year":"2007","unstructured":"Tsareva SA, Moriggl R, Corvinus FM, Wiederanders B, Sch\u00fctz A, Kovacic B, et al. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia. 2007;9(4):279\u201391. https:\/\/doi.org\/10.1593\/neo.06820.","journal-title":"Neoplasia"},{"key":"1220_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw363.71","volume":"27","author":"D Yokom","year":"2016","unstructured":"Yokom D, Sud S, Marginean H, Asmis T, Jonker DJ, Martel G, et al. Signal transducer and activator of transcription 3 (STAT3) expression concordance in paired primary and metastatic colorectal cancers (mCRC). Ann Oncol. 2016;27:vi38. https:\/\/doi.org\/10.1093\/annonc\/mdw363.71.","journal-title":"Ann Oncol"},{"issue":"2","key":"1220_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100996","volume":"14","author":"EC Marginean","year":"2021","unstructured":"Marginean EC, Gotfrit J, Marginean H, Yokom DW, Bateman JJ, Daneshmand M, et al. Phosphorylated transducer and activator of transcription-3 (pSTAT3) immunohistochemical expression in paired primary and metastatic colorectal cancer. Translat Oncol. 2021;14(2):100996. https:\/\/doi.org\/10.1016\/j.tranon.2020.100996.","journal-title":"Translat Oncol"},{"issue":"1","key":"1220_CR69","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.bbrc.2018.02.084","volume":"497","author":"W Li","year":"2018","unstructured":"Li W, Lee MR, Kim T, Kim YW, Cho MY. Activated STAT3 may participate in tumor progression through increasing CD133\/survivin expression in early stage of colon cancer. Biochem Biophys Res Commun. 2018;497(1):354\u201361. https:\/\/doi.org\/10.1016\/j.bbrc.2018.02.084.","journal-title":"Biochem Biophys Res Commun"},{"key":"1220_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102907","volume":"151","author":"SM Zunder","year":"2020","unstructured":"Zunder SM, Gelderblom H, Tollenaar RA, Mesker WE. The significance of stromal collagen organization in cancer tissue: an in-depth discussion of literature. Crit Rev Oncol Hematol. 2020;151:102907. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102907.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1220_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1.","journal-title":"Mol Cancer"},{"key":"1220_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2013.12.005","volume":"25","author":"J Harper","year":"2014","unstructured":"Harper J, Sainson RCA. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin Cancer Biol. 2014;25:69\u201377. https:\/\/doi.org\/10.1016\/j.semcancer.2013.12.005.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1220_CR73","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clcc.2022.11.002","volume":"22","author":"MA Shah","year":"2023","unstructured":"Shah MA, Yoshino T, Tebbutt NC, Grothey A, Tabernero J, Xu RH, et al. Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C study. Clin Colorectal Cancer. 2023;22(1):100\u201310. https:\/\/doi.org\/10.1016\/j.clcc.2022.11.002.","journal-title":"Clin Colorectal Cancer"},{"key":"1220_CR74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","volume":"85","author":"J Jiang","year":"2022","unstructured":"Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol. 2022;85:107\u201322. https:\/\/doi.org\/10.1016\/j.semcancer.2021.04.003.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1220_CR75","doi-asserted-by":"publisher","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","volume":"18","author":"AM Skoda","year":"2018","unstructured":"Skoda AM, Simovic D, Karin V, Kardum V, Vranic S, Serman L. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn J Basic Med Sci. 2018;18(1):8\u201320. https:\/\/doi.org\/10.17305\/bjbms.2018.2756.","journal-title":"Bosn J Basic Med Sci"},{"issue":"6929","key":"1220_CR76","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature01493","volume":"422","author":"DN Watkins","year":"2003","unstructured":"Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003;422(6929):313\u20137. https:\/\/doi.org\/10.1038\/nature01493.","journal-title":"Nature"},{"issue":"7009","key":"1220_CR77","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nature02962","volume":"431","author":"SS Karhadkar","year":"2004","unstructured":"Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431(7009):707\u201312. https:\/\/doi.org\/10.1038\/nature02962.","journal-title":"Nature"},{"issue":"4","key":"1220_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041098","volume":"19","author":"T Usui","year":"2018","unstructured":"Usui T, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H, et al. Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture. Int J Mol Sci. 2018;19(4):1098. https:\/\/doi.org\/10.3390\/ijms19041098.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1220_CR79","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1113713.","journal-title":"N Engl J Med"},{"issue":"36","key":"1220_CR80","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1200\/jco.2015.62.8719","volume":"33","author":"DV Catenacci","year":"2015","unstructured":"Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, et al. Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol. 2015;33(36):4284\u201392. https:\/\/doi.org\/10.1200\/jco.2015.62.8719.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1220_CR81","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/annonc\/mdw138","volume":"27","author":"R Houot","year":"2016","unstructured":"Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, et al. Inhibition of hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. Ann Oncol. 2016;27(7):1349\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdw138.","journal-title":"Ann Oncol"},{"issue":"11","key":"1220_CR82","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1093\/annonc\/mdt391","volume":"24","author":"A Italiano","year":"2013","unstructured":"Italiano A, Le Cesne A, Bellera C, Piperno-Neumann S, Duffaud F, Penel N, et al. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group\/US and French National Cancer Institute single-arm phase II collaborative study. Ann Oncol. 2013;24(11):2922\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdt391.","journal-title":"Ann Oncol"},{"issue":"1","key":"1220_CR83","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/1078-0432.Ccr-12-1800","volume":"19","author":"J Berlin","year":"2013","unstructured":"Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013;19(1):258\u201367. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-1800.","journal-title":"Clin Cancer Res"},{"issue":"7015","key":"1220_CR84","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature03096","volume":"432","author":"NA Bhowmick","year":"2004","unstructured":"Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332\u20137. https:\/\/doi.org\/10.1038\/nature03096.","journal-title":"Nature"},{"issue":"9","key":"1220_CR85","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nm.2208","volume":"16","author":"V Barry-Hamilton","year":"2010","unstructured":"Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of Lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009\u201317. https:\/\/doi.org\/10.1038\/nm.2208.","journal-title":"Nat Med"},{"issue":"10","key":"1220_CR86","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1093\/carcin\/bgt241","volume":"34","author":"S Zaffryar-Eilot","year":"2013","unstructured":"Zaffryar-Eilot S, Marshall D, Voloshin T, Bar-Zion A, Spangler R, Kessler O, et al. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis. 2013;34(10):2370\u20139. https:\/\/doi.org\/10.1093\/carcin\/bgt241.","journal-title":"Carcinogenesis"},{"issue":"2","key":"1220_CR87","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3892\/or.2018.6452","volume":"40","author":"X Cui","year":"2018","unstructured":"Cui X, Wang G, Shen W, Huang Z, He H, Cui L. Lysyl oxidase-like 2 is highly expressed in colorectal cancer cells and promotes the development of colorectal cancer. Oncol Rep. 2018;40(2):932\u201342. https:\/\/doi.org\/10.3892\/or.2018.6452.","journal-title":"Oncol Rep"},{"issue":"46","key":"1220_CR88","doi-asserted-by":"publisher","first-page":"80325","DOI":"10.18632\/oncotarget.18170","volume":"8","author":"PG Park","year":"2017","unstructured":"Park PG, Jo SJ, Kim MJ, Kim HJ, Lee JH, Park CK, et al. Role of LOXL2 in the epithelial-mesenchymal transition and colorectal cancer metastasis. Oncotarget. 2017;8(46):80325\u201335. https:\/\/doi.org\/10.18632\/oncotarget.18170.","journal-title":"Oncotarget"},{"issue":"3","key":"1220_CR89","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1634\/theoncologist.2016-0479","volume":"22","author":"JR Hecht","year":"2017","unstructured":"Hecht JR, Benson AB 3rd, Vyushkov D, Yang Y, Bendell J, Verma U. A phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the second-line treatment of metastatic KRAS mutant colorectal adenocarcinoma. Oncologist. 2017;22(3):243-e23. https:\/\/doi.org\/10.1634\/theoncologist.2016-0479.","journal-title":"Oncologist"},{"issue":"2","key":"1220_CR90","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9 J. TGF\u03b2 in cancer. Cell. 2008;134(2):215\u201330. https:\/\/doi.org\/10.1016\/j.cell.2008.07.001.","journal-title":"Cell"},{"issue":"5","key":"1220_CR91","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","volume":"22","author":"A Calon","year":"2012","unstructured":"Calon A, Espinet E, Palomo-Ponce S, Tauriello DVF, Iglesias M, C\u00e9spedes MV, et al. Dependency of colorectal cancer on a TGF-\u03b2-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571\u201384. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.013.","journal-title":"Cancer Cell"},{"key":"1220_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051294","author":"L Caja","year":"2018","unstructured":"Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, et al. TGF-\u03b2 and the tissue microenvironment: relevance in fibrosis and cancer. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19051294.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1220_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55687-6","volume":"10","author":"J Bauer","year":"2020","unstructured":"Bauer J, Emon MAB, Staudacher JJ, Thomas AL, Zessner-Spitzenberg J, Mancinelli G, et al. Increased stiffness of the tumor microenvironment in colon cancer stimulates cancer associated fibroblast-mediated prometastatic Activin A signaling. Sci Rep. 2020;10(1):50. https:\/\/doi.org\/10.1038\/s41598-019-55687-6.","journal-title":"Sci Rep"},{"issue":"6005","key":"1220_CR94","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.1195300","volume":"330","author":"M Kraman","year":"2010","unstructured":"Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein\u2013\u03b1. Science. 2010;330(6005):827\u201330. https:\/\/doi.org\/10.1126\/science.1195300.","journal-title":"Science"},{"issue":"3","key":"1220_CR95","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1220_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei L, Liu Y, Liu L, Gao S, Gao X, Feng Y, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):29. https:\/\/doi.org\/10.1186\/s12943-023-01731-z.","journal-title":"Mol Cancer"},{"issue":"10","key":"1220_CR97","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst RJ, Hata A. Targeting the TGF\u03b2 signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790\u2013811. https:\/\/doi.org\/10.1038\/nrd3810.","journal-title":"Nat Rev Drug Discov"},{"key":"1220_CR98","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-4419-6033-7_5","volume":"155","author":"N Bellam","year":"2010","unstructured":"Bellam N, Pasche B. Tgf-beta signaling alterations and colon cancer. Cancer Treat Res. 2010;155:85\u2013103. https:\/\/doi.org\/10.1007\/978-1-4419-6033-7_5.","journal-title":"Cancer Treat Res"},{"issue":"1","key":"1220_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15404-8","volume":"11","author":"AJ Gunderson","year":"2020","unstructured":"Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, Alice A, et al. TGF\u03b2 suppresses CD8(+) T cell expression of CXCR3 and tumor trafficking. Nat Commun. 2020;11(1):1749. https:\/\/doi.org\/10.1038\/s41467-020-15404-8.","journal-title":"Nat Commun"},{"issue":"7","key":"1220_CR100","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s1470-2045(12)70187-0","volume":"13","author":"C R\u00f6del","year":"2012","unstructured":"R\u00f6del C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679\u201387. https:\/\/doi.org\/10.1016\/s1470-2045(12)70187-0.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1220_CR101","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/s1470-2045(22)00446-6","volume":"23","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol. 2022;23(9):1189\u2013200. https:\/\/doi.org\/10.1016\/s1470-2045(22)00446-6.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1220_CR102","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s11605-017-3408-z","volume":"21","author":"AM Dinaux","year":"2017","unstructured":"Dinaux AM, Amri R, Bordeianou LG, Hong TS, Wo JY, Blaszkowsky LS, et al. The impact of pathologic complete response in patients with neoadjuvantly treated locally advanced rectal cancer\u2014a large single-center experience. J Gastrointest Surg. 2017;21(7):1153\u20138. https:\/\/doi.org\/10.1007\/s11605-017-3408-z.","journal-title":"J Gastrointest Surg"},{"issue":"8","key":"1220_CR103","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s1470-2045(15)00004-2","volume":"16","author":"J Garcia-Aguilar","year":"2015","unstructured":"Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(15)00004-2.","journal-title":"Lancet Oncol"},{"issue":"23","key":"1220_CR104","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/jco.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546\u201356. https:\/\/doi.org\/10.1200\/jco.22.00032.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1220_CR105","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41416-023-02500-x","volume":"130","author":"E K\u00fc\u00e7\u00fckk\u00f6se","year":"2024","unstructured":"K\u00fc\u00e7\u00fckk\u00f6se E, Baars MJD, Amini M, Schraa SJ, Floor E, Bol GM, et al. Stromal localization of inactive CD8(+) T cells in metastatic mismatch repair deficient colorectal cancer. Br J Cancer. 2024;130(2):213\u201323. https:\/\/doi.org\/10.1038\/s41416-023-02500-x.","journal-title":"Br J Cancer"},{"issue":"7","key":"1220_CR106","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669\u201385. https:\/\/doi.org\/10.1001\/jama.2021.0106.","journal-title":"JAMA"},{"issue":"1","key":"1220_CR107","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/intimm\/dxu095","volume":"27","author":"GK Philips","year":"2015","unstructured":"Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27(1):39\u201346. https:\/\/doi.org\/10.1093\/intimm\/dxu095.","journal-title":"Int Immunol"},{"issue":"5","key":"1220_CR108","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111\u201322. https:\/\/doi.org\/10.1080\/21645515.2019.1571892.","journal-title":"Hum Vaccin Immunother"},{"issue":"21","key":"1220_CR109","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1158\/1078-0432.Ccr-13-0694","volume":"19","author":"M Herrera","year":"2013","unstructured":"Herrera M, Islam AB, Herrera A, Mart\u00edn P, Garc\u00eda V, Silva J, et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res. 2013;19(21):5914\u201326. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0694.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1220_CR110","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36(3):277\u201384. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.012.","journal-title":"Ann Oncol"},{"issue":"25","key":"1220_CR111","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2201445.","journal-title":"N Engl J Med"},{"issue":"21","key":"1220_CR112","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Lent AUV, Grootscholten C, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient colon cancer. N Engl J Med. 2024;390(21):1949\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2400634.","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"1220_CR113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1","volume":"43","author":"FA Sinicrope","year":"2025","unstructured":"Sinicrope FA, Ou F-S, Arnold D, Peters W, Behrens RJ, Lieu CH, et al. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). J Clin Oncol. 2025;43(17_suppl):LBA1. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA1.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1220_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54710-3","volume":"15","author":"Y Feng","year":"2024","unstructured":"Feng Y, Ma W, Zang Y, Guo Y, Li Y, Zhang Y, et al. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients. Nat Commun. 2024;15(1):10259. https:\/\/doi.org\/10.1038\/s41467-024-54710-3.","journal-title":"Nat Commun"},{"issue":"6","key":"1220_CR115","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.Ccr-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287\u201395. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2653.","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"1220_CR116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9017","volume":"36","author":"LG Paz-Ares","year":"2018","unstructured":"Paz-Ares LG, Kim TM, Baz DV, Felip E, Lee DH, Lee KH, et al. Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1. J Clin Oncol. 2018;36(15_suppl):9017. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.9017.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1220_CR117","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1158\/1078-0432.Ccr-22-0346","volume":"28","author":"J Feng","year":"2022","unstructured":"Feng J, Tang D, Wang J, Zhou Q, Peng J, Lou H, et al. SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, for recurrent or metastatic cervical cancer: a clinical expansion cohort of a phase I study. Clin Cancer Res. 2022;28(24):5297\u2013305. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0346.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1220_CR118","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1093\/oncolo\/oyac254","volume":"28","author":"A Spira","year":"2023","unstructured":"Spira A, Wertheim MS, Kim EJ, Tan B, Lenz HJ, Nikolinakos P, et al. Bintrafusp alfa: a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with pretreated colorectal cancer: results from a phase I trial. Oncologist. 2023;28(2):e124\u20137. https:\/\/doi.org\/10.1093\/oncolo\/oyac254.","journal-title":"Oncologist"},{"issue":"1","key":"1220_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02063-0","volume":"9","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Bai Y, Wang J, Gu K, Yang M, He Y, et al. Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. Signal Transduct Target Ther. 2024;9(1):349. https:\/\/doi.org\/10.1038\/s41392-024-02063-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1220_CR120","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-0043-1761447","volume":"37","author":"MIM Ilyas","year":"2024","unstructured":"Ilyas MIM. Epidemiology of stage IV colorectal cancer: trends in the incidence, prevalence, age distribution, and impact on life span. Clin Colon Rectal Surg. 2024;37(2):57\u201361. https:\/\/doi.org\/10.1055\/s-0043-1761447.","journal-title":"Clin Colon Rectal Surg"},{"issue":"1","key":"1220_CR121","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/cjp2.143","volume":"6","author":"JH Park","year":"2020","unstructured":"Park JH, van Wyk H, McMillan DC, Edwards J, Orange C, Horgan PG, et al. Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. J Pathol Clin Res. 2020;6(1):30\u20139. https:\/\/doi.org\/10.1002\/cjp2.143.","journal-title":"J Pathol Clin Res"},{"key":"1220_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2022.101862","volume":"45","author":"MTA Strous","year":"2022","unstructured":"Strous MTA, Faes TKE, Heemskerk J, Lohman B, Simons PCG, Janssen Heijnen MLG, et al. Tumour-stroma ratio to predict pathological response to neo-adjuvant treatment in rectal cancer. Surg Oncol. 2022;45:101862. https:\/\/doi.org\/10.1016\/j.suronc.2022.101862.","journal-title":"Surg Oncol"},{"issue":"8","key":"1220_CR123","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541\u201352. https:\/\/doi.org\/10.1200\/JCO.22.00046.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1220_CR124","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM-K, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(20)30555-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1220_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00488-4","volume":"8","author":"A Valdeolivas","year":"2024","unstructured":"Valdeolivas A, Amberg B, Giroud N, Richardson M, G\u00e1lvez EJC, Badillo S, et al. Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics. npj Precis Oncol. 2024;8(1):10. https:\/\/doi.org\/10.1038\/s41698-023-00488-4.","journal-title":"npj Precis Oncol"},{"issue":"26","key":"1220_CR126","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1500596.","journal-title":"N Engl J Med"},{"issue":"1","key":"1220_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24(1):20. https:\/\/doi.org\/10.1186\/s12943-024-02212-7.","journal-title":"Mol Cancer"},{"issue":"12","key":"1220_CR128","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1158\/0008-5472.Can-24-4744","volume":"85","author":"L Liu","year":"2025","unstructured":"Liu L, Zhang Y, Liu H, Yang J, Tian Q, Chueakula N, et al. Transforming cancer therapy: unlocking the potential of targeting vascular and stromal cells in the tumor microenvironment. Cancer Res. 2025;85(12):2152\u201364. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-4744.","journal-title":"Cancer Res"},{"issue":"1","key":"1220_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01611-0","volume":"39","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida GJ. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 2020;39(1):112. https:\/\/doi.org\/10.1186\/s13046-020-01611-0.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01220-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:55:00Z","timestamp":1780131300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01220-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01220-5","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"27 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Bollenstreekfonds, Hillegom, the Netherlands. The funder had no role in study design data collection, and analysis, or in decision to publish, or in the preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Floor Heilijgers, Marie-Christine Bakker, Bente van Hest, Ingrid Franken, Frank M. Speetjens, Koen C. M. J. Peeters, Jeanine Roodhart, and Wilma E. Mesker declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent for Publication, Availability of Data and Material, Code Availability"}},{"value":"Floor Heilijgers: conceptualization, methodology, data curation, writing\u2014original draft, writing\u2014review and editing, investigation. Marie-Christine Bakker: conceptualization, writing\u2014review and editing. Bente van Hest: data curation. Ingrid Franken: writing\u2014review and editing. Frank M. Speetjens: writing\u2014review and editing. Koen C. M. J. Peeters: writing\u2014review and editing. Jeanine Roodhart: writing\u2014review and editing. Wilma E. Mesker: conceptualization, supervision, writing\u2014review and editing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contribution"}}]}}